Loading company…
Yoltech Therapeutics develops mRNA and gene-editing drugs for hereditary, cardiovascular and other diseases.
Founded in 2021, Yoltech Therapeutics develops mRNA and gene-editing drugs, including treatments for metabolic, genetic and infectious diseases. It is based in Shanghai, China. In May 2026, it raised nearly CNY 500 million in Series C funding led by Loyal Valley Capital, with participation from Shanghai State-owned Capital Investment Leading Fund, Shanghai Minhang Financial Investment Development, Deyue Investment, K2VC, Grand Flight Investment, Tianjin Venture Capital and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in